The pharmaceutical industry faces mounting regulatory challenges that significantly impact clinical trial conduct and new drug application success. This thesis provides a comprehensive examination of regulatory obstacles across the drug development lifecycle, from protocol design through post-approval surveillance. Through systematic analysis of regulatory frameworks, literature synthesis, and empirical data evaluation, this research identifies critical challenge domains including escalating protocol complexity, patient recruitment difficulties, divergent global requirements, and post-approval commitment fulfillment gaps. Quantitative analysis reveals median protocol amendment rates of 3.8 per Phase III trial, with only 34.2% of trials meeting enrollment timelines. Approval timeline analysis demonstrates improvements in regulatory review efficiency, with median FDA priority review times decreasing from 7.8 to 6.2 months over the study period. However, concerning trends emerged in accelerated approval oversight, with 42% of confirmatory trials incomplete or not initiated. The research highlights substantial therapeutic area variations in regulatory challenges, with oncology and CNS disorders experiencing particular complexity. Post-approval safety actions affected 37.8% of approved drugs within five years, emphasizing ongoing pharmacovigilance importance.

Clinical trials, regulatory challenges, new drug applications, pharmaceutical development, drug approval processes